Zacks Research Issues Positive Forecast for RDY Earnings

Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Investment analysts at Zacks Research lifted their Q2 2026 earnings estimates for Dr. Reddy's Laboratories in a report issued on Wednesday, October 16th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.00 per share for the quarter, up from their previous estimate of $0.99. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $4.11 per share. Zacks Research also issued estimates for Dr. Reddy's Laboratories' Q3 2026 earnings at $1.01 EPS and FY2026 earnings at $4.07 EPS.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Saturday, July 27th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by ($0.10). Dr. Reddy's Laboratories had a net margin of 19.28% and a return on equity of 20.32%. The business had revenue of $919.80 million for the quarter, compared to analysts' expectations of $861.68 million.

Separately, Barclays boosted their target price on Dr. Reddy's Laboratories from $81.00 to $87.00 and gave the company an "overweight" rating in a research report on Tuesday, July 30th.

Dr. Reddy's Laboratories Trading Up 0.8 %

NYSE RDY traded up $0.60 during trading hours on Thursday, hitting $79.80. 127,994 shares of the company were exchanged, compared to its average volume of 213,237. Dr. Reddy's Laboratories has a 52 week low of $63.72 and a 52 week high of $84.46. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average price of $80.46 and a 200 day moving average price of $76.31. The stock has a market cap of $13.32 billion, a PE ratio of 19.80, a price-to-earnings-growth ratio of 1.73 and a beta of 0.55.

Hedge Funds Weigh In On Dr. Reddy's Laboratories

Several hedge funds have recently added to or reduced their stakes in RDY. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of Dr. Reddy's Laboratories by 318.0% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company's stock valued at $28,411,000 after buying an additional 283,700 shares during the period. Millennium Management LLC grew its position in Dr. Reddy's Laboratories by 61.4% in the 2nd quarter. Millennium Management LLC now owns 332,502 shares of the company's stock valued at $25,333,000 after acquiring an additional 126,472 shares during the last quarter. Fisher Asset Management LLC grew its position in Dr. Reddy's Laboratories by 126.5% in the 4th quarter. Fisher Asset Management LLC now owns 205,280 shares of the company's stock valued at $14,283,000 after acquiring an additional 114,630 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Dr. Reddy's Laboratories by 12.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock worth $76,455,000 after purchasing an additional 114,294 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Dr. Reddy's Laboratories by 2,197.8% during the first quarter. Jane Street Group LLC now owns 113,168 shares of the company's stock worth $8,301,000 after purchasing an additional 108,243 shares during the last quarter. 14.02% of the stock is currently owned by institutional investors.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.